This month (Jan 2015) Switzerland was the first country to launch Novo Nordisk’s Xultophy (IDegLira) for people with Type 2 diabetes. Xultophy is the first combination of a basal insulin (Tresiba, insulin degludec) and a GLP-1 analogue (Victoza, liraglutide). Xultophy is administered read more »